603127 昭衍新药
2025/06 - 中期
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
2021/12
人民币(K¥)
经营活动产生之现金流量净额162,773338,929622,875971,066685,655
投资活动产生之现金流量净额(435,012)(1,963,024)(315,429)(2,160,131)(2,069,807)
筹资活动产生之现金流量净额(28,180)(265,627)(361,678)(99,332)5,290,402
汇率变动对现金及现金等价物的影响(2,551)1,2798,41037,470(60,898)
现金及现金等价物净增加/(减少)(302,971)(1,888,444)(45,823)(1,250,927)3,845,352
期初现金及现金等价物余额965,2032,853,6472,899,4704,150,396305,044
期末现金及现金等价物余额662,232965,2032,853,6472,899,4704,150,396